Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management

Overview

Journal Curr Transplant Rep

Date 2016 Sep 23

PMID 27656351

Citations 8

Authors

Carrie Schinstock

Mark D Stegall

Affiliations

Soon will be listed here.

Abstract

Acute antibody mediated rejection (AMR) is recognized as a major cause of graft loss in renal transplant recipients. Early acute AMR in the first few days after transplantation occurs primarily in sensitized renal transplant recipients with donor-specific alloantibody at the time of transplant and is a relatively "pure" form of acute AMR. Late acute AMR occurs months to years after transplantation and is commonly a mixed cellular and humoral rejection. While there is no consensus regarding optimum treatment, we contend that rational therapeutic approaches are emerging and the acute episode can be managed in most instances. However, new therapies are needed to prevent ongoing chronic injury in these patients.

Citing Articles

Characteristics of Early Antibody Mediated Rejection in Antibody Incompatible Living Donor Kidney Transplantation.

Punjala S, Ibrahim M, Phillips B, Stojanovic J, Kessaris N, Shaw O Transpl Int. 2024; 37:12942.

PMID: 39040870 PMC: 11261346. DOI: 10.3389/ti.2024.12942.

Successful treatment of early acute antibody-mediated rejection in an human leukocyte antigen-incompatible and ABO-incompatible living-donor kidney transplant patient.

Gang S, Han A, Min S, Ha J, Yang J Korean J Transplant. 2022; 33(4):153-158.

PMID: 35769976 PMC: 9188936. DOI: 10.4285/jkstn.2019.33.4.153.

Histopathologic Features of Antibody Mediated Rejection: The Banff Classification and Beyond.

Cornell L Front Immunol. 2021; 12:718122.

PMID: 34646262 PMC: 8503253. DOI: 10.3389/fimmu.2021.718122.

Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage.

Franzin R, Stasi A, Fiorentino M, Stallone G, Cantaluppi V, Gesualdo L Front Immunol. 2020; 11:734.

PMID: 32457738 PMC: 7221190. DOI: 10.3389/fimmu.2020.00734.

Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.

Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S Am J Transplant. 2019; 19(10):2865-2875.

PMID: 31012541 PMC: 9328661. DOI: 10.1111/ajt.15397.

References

Raghavaiah S, Stegall M . New therapeutic approaches to antibody-mediated rejection in renal transplantation. Clin Pharmacol Ther. 2011; 90(2):310-5. DOI: 10.1038/clpt.2011.123. View

GURLAND H, Blumenstein M, Lysaght M, Samtleben W, Stoffner D . Plasmapheresis in renal transplantation. Kidney Int Suppl. 1983; (14):S-82-4. View

Kaplan B, Jie T, Diana R, Renz J, Whinery A, Stubbs N . Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection. Am J Transplant. 2010; 10(5):1316-20. DOI: 10.1111/j.1600-6143.2010.03067.x. View

Blake P, Sutton D, Cardella C . Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res. 1990; 337:249-52. View

Zhang X, Reed E . Effect of antibodies on endothelium. Am J Transplant. 2009; 9(11):2459-65. PMC: 4412741. DOI: 10.1111/j.1600-6143.2009.02819.x. View

Glotz D, Haymann J, Sansonetti N, Francois A, Bariety J, Druet P . Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation. 1993; 56(2):335-7. DOI: 10.1097/00007890-199308000-00015. View

Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D . Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009; 9(5):1099-107. DOI: 10.1111/j.1600-6143.2009.02591.x. View

Tzvetanov I, Spaggiari M, Oberholzer J, Setty S, Stephenson A, Thielke J . Cell population in spleens during antibody-mediated rejection: pathologic and clinical findings. Transplantation. 2012; 94(3):255-62. DOI: 10.1097/TP.0b013e3182562881. View

Sis B, Halloran P . Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant. 2009; 15(1):42-8. DOI: 10.1097/MOT.0b013e3283352a50. View

10.

Cassese G, Arce S, Hauser A, Lehnert K, Moewes B, Mostarac M . Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003; 171(4):1684-90. DOI: 10.4049/jimmunol.171.4.1684. View

11.

Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R . Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant. 2010; 10(3):681-6. DOI: 10.1111/j.1600-6143.2009.02968.x. View

12.

Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M . Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007; 67(4):1783-92. DOI: 10.1158/0008-5472.CAN-06-2258. View

13.

Perry D, Burns J, Pollinger H, Amiot B, Gloor J, Gores G . Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2008; 9(1):201-9. DOI: 10.1111/j.1600-6143.2008.02461.x. View

14.

Vo A, Cam V, Toyoda M, Puliyanda D, Lukovsky M, Bunnapradist S . Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol. 2007; 1(4):844-52. DOI: 10.2215/CJN.01701105. View

15.

Roberts D, Jiang S, Chadban S . The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012; 94(8):775-83. DOI: 10.1097/TP.0b013e31825d1587. View

16.

Luke P, Scantlebury V, Jordan M, Vivas C, Hakala T, Jain A . Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation. 2001; 72(3):419-22. DOI: 10.1097/00007890-200108150-00010. View

17.

Jordan S, Quartel A, Czer L, Admon D, Chen G, Fishbein M . Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998; 66(6):800-5. DOI: 10.1097/00007890-199809270-00017. View

18.

Everly M, Everly J, Susskind B, Brailey P, Arend L, Alloway R . Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008; 86(12):1754-61. DOI: 10.1097/TP.0b013e318190af83. View

19.

Kirubakaran M, Disney A, Norman J, Pugsley D, MATHEW T . A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation. 1981; 32(2):164-5. DOI: 10.1097/00007890-198108000-00019. View

20.

Sanz I, Wei C, Lee F, Anolik J . Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008; 20(1):67-82. PMC: 2440717. DOI: 10.1016/j.smim.2007.12.006. View